For research use only.
CAS No. 172732-68-2
Varespladib (LY315920) is a potent and selective human non-pancreatic secretory phospholipase A2 (hnsPLA) inhibitor with IC50 of 7 nM. Phase 3.
Selleck's Varespladib (LY315920) has been cited by 8 publications
3 Customer Reviews
Hepatic immune cell infiltration in Mmp2 −/− mice administered the pan-sPLA 2 inhibitor varespladib (10 mg/kg per day, gavage, for 5 days). Collagenase-treated and liberated cells were surface-stained for indicated markers (A) and quantitated. n=3 WT and n=5 Mmp2 −/−. *P≤0.05 vs WT untreated. † P≤0.05 vs Mmp2 −/− untreated. MHC II, major histocompatibility complex II; sPLA2, secreted phospholipase A2; SSC, Side-scattered light (a magnitude proportional to cell granularity or internal complexity); WT, wild type.
J Am Heart Assoc, 2015, 4:e002553.. Varespladib (LY315920) purchased from Selleck.
Cells were treated with inhibitors for cPLA2α (5 μM Inhibitor 28, 1 μM CAY10502, 5 μM AVX002, 5 μM ATK); sPLA2 (10 μM CAY10590, 10 μM Varespladib) or COX1/2 (10 μM Indomethasin) for 2 hours followed by FSL-1 (100 ng/mL) or Pam3CSK4 (200 ng/mL) for 24 hours. Release of PGE2 was measured by ELISA. Results shown are mean ± SD of three independent experiments.
PLoS One, 2015, 10(4):e0119088.. Varespladib (LY315920) purchased from Selleck.
After serum deprivation for 48 h (A) or 24 h (B) MDA-MB-231 cells were treated with recombinant hGX (10 nM) in serum-free medium containing 0.1% FAF BSA for 24 h (A) or 96 h (B) in the presence or absence of the sPLA2 inhibitor varespladib (Var) at a final concentration of 50 μM.
Mol Cancer, 2013, 12(1):111.. Varespladib (LY315920) purchased from Selleck.
Purity & Quality Control
Choose Selective Phospholipase (e.g. PLA) Inhibitors
|Description||Varespladib (LY315920) is a potent and selective human non-pancreatic secretory phospholipase A2 (hnsPLA) inhibitor with IC50 of 7 nM. Phase 3.|
|Features||A potent and selective secretory phospholipase A2 inhibitor.|
LY315920 exhibits the significant inhibitory effect on sPLA2 activity in serum from various species including rat, rabbit, guinea pig and human with IC50 of 8.1 nM, 5.0 nM, 3.2 nM and 6.2 nM, respectively.  In BAL cells challenged with human sPLA2, LY315920 at doses ranging from 0.1 μM–3 μM reduces the formation of thromboxane mediated by human sPLA2 in a concentration-dependent manner with an IC50 of approximately 0.8 μM.  In human conjunctival epithelial cell line (HCjE), LY315920 (10 μM) significantly inhibits all-trans-retinoic acid (RA) -induced membrane-associated mucin MUC16 expression by 100% at 24 hours and 99% at 48 hours. 
|In vivo||Ex vivo, LY315920 at doses ranging from 3 mg/kg to 30 mg/kg via i.v. inhibits human sPLA2-induced release of thromboxane from guinea pig BAL cells with ED50 of 16.1 mg/kg.  In Transgenic Mice Expressing Human sPLA2, both oral and i.v. administration of LY315920 (0.3 mg/kg–3 mg/kg) abolishes serum sPLA2 activity in a dose and time dependent manner. |
|In vitro||DMSO||76 mg/mL (199.79 mM)|
|In vivo||Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O
For best results, use promptly after mixing.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
In vivo Formulation Calculator (Clear solution)
|Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)|
|Dosage||mg/kg||Average weight of animals||g||Dosing volume per animal||ul||Number of animals|
|Step 2: Enter the in vivo formulation ()|
|% DMSO % % Tween 80 % ddH2O|
Working concentration： mg/ml；
Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL，)
Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH2O，mix and clarify.
1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT01359605||Completed||Drug: varespladib methyl||Healthy Volunteers||Anthera Pharmaceuticals||June 2011||Phase 1|
|NCT01359579||Terminated||Drug: varespladib methyl||Renal Impairment||Anthera Pharmaceuticals||June 2011||Phase 1|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.